{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:09:58Z","timestamp":1762272598360,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a pressing need to improve the efficiency of drug development, and nowhere is that need more clear than in the case of neglected diseases like malaria. The peculiarities of pyrimidine metabolism in <jats:italic>Plasmodium<\/jats:italic> species make inhibition of dihydroorotate dehydrogenase (DHODH) an attractive target for antimalarial drug design. By applying a pair of complementary quantitative structure\u2013activity relationships derived for inhibition of a truncated, soluble form of the enzyme from <jats:italic>Plasmodium falciparum <\/jats:italic>(s-<jats:italic>Pf<\/jats:italic>DHODH) to data from a large-scale phenotypic screen against cultured parasites, we were able to identify a class of antimalarial leads that inhibit the enzyme and abolish parasite growth in blood culture. Novel analogs extending that class were designed and synthesized with a goal of improving potency as well as the general pharmacokinetic and toxicological profiles. Their synthesis also represented an opportunity to prospectively validate our in silico property predictions. The seven analogs synthesized exhibited physicochemical properties in good agreement with prediction, and five of them were more active against <jats:italic>P. falciparum<\/jats:italic> growing in blood culture than any of the compounds in the published lead series. The particular analogs prepared did not inhibit s-<jats:italic>Pf<\/jats:italic>DHODH in vitro, but advanced biological assays indicated that other examples from the class did inhibit intact <jats:italic>Pf<\/jats:italic>DHODH bound to the mitochondrial membrane. The new analogs, however, killed the parasites by acting through some other, unidentified mechanism 24\u201348\u00a0h before <jats:italic>Pf<\/jats:italic>DHODH inhibition would be expected to do so.<\/jats:p>","DOI":"10.1007\/s10822-020-00333-x","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T04:03:36Z","timestamp":1598241816000},"page":"1117-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Design and tests of prospective property predictions for novel antimalarial 2-aminopropylaminoquinolones"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9509-8132","authenticated-orcid":false,"given":"Robert D.","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise N.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Chinigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Lawless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Prudhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4862-9292","authenticated-orcid":false,"given":"Karine G.","family":"Le Roch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-551X","authenticated-orcid":false,"given":"Santiago","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Gamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gadwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter S.","family":"Woltosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"333_CR1","unstructured":"World Health Organization (2019) World malaria report 2019. https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2019\/report\/en\/. Accessed 7 Apr 2020"},{"key":"333_CR2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","volume":"14","author":"TNC Wells","year":"2015","unstructured":"Wells TNC, van Huijsduijnen RH, Van Voorhis WC (2015) Malaria medicines: a glass half full? Nat Rev Drug Discov 14:424\u2013442","journal-title":"Nat Rev Drug Discov"},{"issue":"3 Suppl","key":"333_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4269\/ajtmh.15-0007","volume":"93","author":"L Cui","year":"2015","unstructured":"Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ (2015) Antimalarial drug resistance: literature review and activities and findings of the ICEMR network. Am J Trop Med Hyg 93(3 Suppl):57\u201368","journal-title":"Am J Trop Med Hyg"},{"key":"333_CR4","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1021\/jm040108f","volume":"47","author":"AK Bhattacharjee","year":"2004","unstructured":"Bhattacharjee AK, Geyer JA, Woodard CL, Kathcart AK, Nichols DA, Prigge ST, Li Z, Mott BT, Waters NC (2004) A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors. J Med Chem 47:5418\u20135426","journal-title":"J Med Chem"},{"key":"333_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/ci300421n","volume":"53","author":"L Zhang","year":"2013","unstructured":"Zhang L, Fourches D, Sedykh A, Zhu H, Golbraikh A, Ekins S, Clark J, Connelly MC, Sigal M, Hodges D, Guiguemde A (2013) Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J Chem Inf Model 53:475\u2013492","journal-title":"J Chem Inf Model"},{"key":"333_CR6","first-page":"139","volume-title":"Handbook of experimental pharmacology: new approaches to drug discovery","author":"MS Lawless","year":"2016","unstructured":"Lawless MS, Waldman M, Fraczkiewicz R, Clark RD (2016) Using cheminformatics in drug discovery. In: Nielsch U, Fuhrmann U, Jaroch S (eds) Handbook of experimental pharmacology: new approaches to drug discovery. Springer, Switzerland, pp 139\u2013168"},{"key":"333_CR7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/187152610791163336","volume":"10","author":"MA Phillips","year":"2010","unstructured":"Phillips MA, Rathod PK (2010) Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets 10:226\u2013239","journal-title":"Infect Disord Drug Targets"},{"key":"333_CR8","doi-asserted-by":"crossref","first-page":"35078","DOI":"10.1074\/jbc.M804990200","volume":"283","author":"V Patel","year":"2008","unstructured":"Patel V, Booker M, Kramer M, Ross L, Celatka CA, Kennedy LM, Dvorin JD, Duraisingh MT, Sliz P, Wirth DF, Clardy J (2008) Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 283:35078\u201335085","journal-title":"J Biol Chem"},{"key":"333_CR9","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1021\/jm8001026","volume":"51","author":"MA Phillips","year":"2008","unstructured":"Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, Baldwin J, Rathod PK (2008) Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J Med Chem 51:3649\u20133653","journal-title":"J Med Chem"},{"key":"333_CR10","doi-asserted-by":"crossref","first-page":"21847","DOI":"10.1074\/jbc.M501100200","volume":"280","author":"J Baldwin","year":"2005","unstructured":"Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA (2005) High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 280:21847\u201321853","journal-title":"J Biol Chem"},{"key":"333_CR11","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1021\/jm800963t","volume":"52","author":"M Davies","year":"2009","unstructured":"Davies M, Heikkila T, McConkey GA, Fishwick CWG, Parsons MR, Johnson AP (2009) Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem 52:2683\u20132693","journal-title":"J Med Chem"},{"key":"333_CR12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1021\/jm060687j","volume":"50","author":"T Heikkil\u00e4","year":"2007","unstructured":"Heikkil\u00e4 T, Ramsey C, Davies M, Galtier C, Stead AM, Johnson AP, Fishwick CW, Boa AN, McConkey GA (2007) Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem 50:186\u2013191","journal-title":"J Med Chem"},{"key":"333_CR13","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1021\/jm801343r","volume":"52","author":"R Gujjar","year":"2009","unstructured":"Gujjar R, Marwaha A, El Mazouni F, White J, White KL, Creason S, Shackleford DM, Baldwin J, Charman WN, Buckner FS, Charman S (2009) Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem 52:1864\u20131872","journal-title":"J Med Chem"},{"key":"333_CR14","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/jm200265b","volume":"54","author":"R Gujjar","year":"2011","unstructured":"Gujjar R, El Mazouni F, White KL, White J, Creason S, Shackleford DM, Deng X, Charman WN, Bathurst I, Burrows J, Floyd DM (2011) Lead-optimization of aryl and aralkyl amine based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in mice. J Med Chem 54:3935\u20133949","journal-title":"J Med Chem"},{"key":"333_CR15","unstructured":"The Binding Database (2012). https:\/\/www.bindingdb.org"},{"key":"333_CR16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1110\/ps.03533004","volume":"13","author":"M Hansen","year":"2004","unstructured":"Hansen M, Le Nours J, Johansson EV, Antal T, Ullrich A, L\u00f6ffler M, Larsen S (2004) Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci 13:1031\u20131042","journal-title":"Protein Sci"},{"key":"333_CR17","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"YC Cheng","year":"1973","unstructured":"Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099\u20133108","journal-title":"Biochem Pharmacol"},{"key":"333_CR18","unstructured":"ADMET Predictor (2020) Simulations Plus, Inc., Lancaster, CA. https:\/\/www.simulations-plus.com"},{"key":"333_CR19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nature09107","volume":"465","author":"FJ Gamo","year":"2010","unstructured":"Gamo FJ, Sanz LM, Vidal J, De Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465:305\u2013310","journal-title":"Nature"},{"key":"333_CR20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.drudis.2010.08.010","volume":"15","author":"S Ekins","year":"2010","unstructured":"Ekins S, Williams AJ (2010) When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? Drug Discov Today 15:812\u2013815","journal-title":"Drug Discov Today"},{"key":"333_CR21","unstructured":"MedChem Studio (2020) Simulations Plus, Inc., Lancaster, CA. https:\/\/www.simulations-plus.com; this functionality has since been subsumed into the MedChem Studio Module of ADMET Predictor"},{"key":"333_CR22","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1073\/pnas.0802982105","volume":"105","author":"D Plouffe","year":"2008","unstructured":"Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adri\u00e1n F, Matzen JT, Anderson P, Nam TG (2008) In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci 105:9059\u20139064","journal-title":"Proc Natl Acad Sci"},{"key":"333_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326","journal-title":"Adv Drug Deliv Rev"},{"key":"333_CR24","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/jm200592f","volume":"54","author":"JM Coteron","year":"2011","unstructured":"Coteron JM, Marco M, Esquivias J, Deng X, White KL, White J, Koltun M, El Mazouni F, Kokkonda S, Katneni K, Bhamidipati R (2011) Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem 54:5540\u20135561","journal-title":"J Med Chem"},{"key":"333_CR25","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bmcl.2008.11.071","volume":"19","author":"CK Dong","year":"2009","unstructured":"Dong CK, Patel V, Yang JC, Dvorin JD, Duraisingh MT, Clardy J, Wirth DF (2009) Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors. Bioorg Med Chem Lett 19:972\u2013975","journal-title":"Bioorg Med Chem Lett"},{"key":"333_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1758-2946-1-8","volume":"1","author":"P Ertl","year":"2009","unstructured":"Ertl P, Schuffenhauer A (2009) Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform 1:8","journal-title":"J Cheminform"},{"key":"333_CR27","unstructured":"Berge JM, Brown P, Elder JS, Forrest AK, Hamprecht DW, Jarvest RL, McNair DJ, Sheppard RJ (2001) Quinolones used as MRS inhibitors and bactericides. US Patent 6320051"},{"key":"333_CR28","unstructured":"GastroPlus (2020) Simulations Plus, Inc., Lancaster, CA. https:\/\/www.simulations-plus.com"},{"key":"333_CR29","unstructured":"Simulations Plus, Inc., Press release (9\/13\/2011) https:\/\/www.irdirect.net\/prviewer\/release\/id\/2168302"},{"key":"333_CR30","unstructured":"Okubo T, Kumagi T, Nakamura T, Abe K, Amada Y, Ishizaka T, Sun X-M, Sekiguchi Y, Sasako S, Shimizu T, Nagatsuka T (2011) Aminopyrrolidine compound. US Patent US8044068B2"},{"key":"333_CR31","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/ps.4935","volume":"74","author":"RD Clark","year":"2018","unstructured":"Clark RD (2018) Predicting mammalian metabolism and toxicity of pesticides in silico. Pest Manage Sci 74:1992\u20132003","journal-title":"Pest Manage Sci"},{"key":"333_CR32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1758-2946-6-34","volume":"6","author":"RD Clark","year":"2014","unstructured":"Clark RD, Liang W, Lee AC, Lawless MS, Fraczkiewicz R, Waldman M (2014) Using beta binomials to estimate classification uncertainty for ensemble models. J Cheminform 6:34","journal-title":"J Cheminform"},{"key":"333_CR33","first-page":"246","volume":"28","author":"JB Houston","year":"2000","unstructured":"Houston JB, Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis\u2013Menten model. Drug Metab Dispos 28:246\u2013254","journal-title":"Drug Metab Dispos"},{"key":"333_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.1986.tb02876.x","volume":"22","author":"S Looareesuwan","year":"1986","unstructured":"Looareesuwan S, White NJ, Chanthavanich PO, Edwards G, Nicholl DD, Bunch C, Warrell DA (1986) Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol 22:31\u201336","journal-title":"Br J Clin Pharmacol"},{"key":"333_CR35","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1021\/jacs.5b01152","volume":"137","author":"ME Daub","year":"2015","unstructured":"Daub ME, Prudhomme J, Le Roch K, Vanderwal CD (2015) Synthesis and potent antimalarial activity of kalihinol B. J Am Chem Soc 137:4912\u20134915","journal-title":"J Am Chem Soc"},{"key":"333_CR36","doi-asserted-by":"crossref","first-page":"e2335","DOI":"10.1371\/journal.pone.0002335","volume":"3","author":"J Prudhomme","year":"2008","unstructured":"Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, Jensen P, Le Roch K (2008) Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS ONE 3:e2335","journal-title":"PLoS ONE"},{"key":"333_CR37","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1021\/jm100057h","volume":"53","author":"S Ray","year":"2010","unstructured":"Ray S, Madrid PB, Catz P, LeValley SE, Furniss MJ, Rausch LL, Guy RK, DeRisi JL, Iyer LV, Green CE, Mirsalis JC (2010) Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J Med Chem 53:3685\u20133695","journal-title":"J Med Chem"},{"key":"333_CR38","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1126\/science.1175667","volume":"325","author":"RE Martin","year":"2009","unstructured":"Martin RE, Marchetti RV, Cowan AI, Howitt SM, Br\u00f6er KK (2009) Chloroquine transport via the malaria parasite\u2019s chloroquine resistance transporter. Science 325:1680\u20131682","journal-title":"Science"},{"key":"333_CR39","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1016\/j.bmcl.2017.07.039","volume":"27","author":"R Kumar","year":"2017","unstructured":"Kumar R, Duffy S, Avery VM, Davis RA (2017) Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid. Biorg Med Chem Lett 27:4091\u20134095","journal-title":"Biorg Med Chem Lett"},{"key":"333_CR40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1475-2875-10-278","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ (2011) The parasite clearance curve. Malar J 10:278","journal-title":"Malar J"},{"key":"333_CR41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","volume":"16","author":"JN Burrows","year":"2017","unstructured":"Burrows JN, Duparc S, Gutteridge WE, van Huijsduijnen RH, Kaszubska W, Macintyre F, Mazzuri S, M\u00f6hrle JJ, Wells TN (2017) New developments in anti-malarial target candidate and product profiles. Malar J 16:26","journal-title":"Malar J"},{"key":"333_CR42","doi-asserted-by":"crossref","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","volume":"7","author":"MA Phillips","year":"2015","unstructured":"Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR (2015) A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 7:296ra111","journal-title":"Sci Transl Med"},{"key":"333_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/B978-0-12-409547-2.12323-6","volume-title":"Comprehensive medicinal chemistry III","author":"R Chaudhari","year":"2017","unstructured":"Chaudhari R, Tan Z, Zhang S (2017) Overview of drug polypharmacology and multitargeted molecular design. In: Wilson AGE (ed) Comprehensive medicinal chemistry III. Elsevier, Oxford, pp 259\u2013275"},{"key":"333_CR44","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1021\/bi00183a033","volume":"33","author":"KK Seymour","year":"1994","unstructured":"Seymour KK, Lyons SD, Phillips L, Rieckmann KH, Christopherson RI (1994) Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry 33:5268\u20135274","journal-title":"Biochemistry"},{"key":"333_CR45","first-page":"312","volume":"D62","author":"DE Hurt","year":"2006","unstructured":"Hurt DE, Widom J, Clardy J (2006) Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Cryst D62:312\u2013323","journal-title":"Acta Cryst"},{"key":"333_CR46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature05572","volume":"446","author":"HJ Painter","year":"2007","unstructured":"Painter HJ, Morrisey JM, Mather MW, Vaidya AB (2007) Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446:88\u201391","journal-title":"Nature"},{"key":"333_CR47","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acsinfecdis.6b00144","volume":"2","author":"MA Phillips","year":"2016","unstructured":"Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, Baldwin J, Rathod PK (2016) A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria. ACS Infect Dis 2:945\u2013957","journal-title":"ACS Infect Dis"},{"key":"333_CR48","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1021\/jm025502x","volume":"45","author":"RL Jarvest","year":"2002","unstructured":"Jarvest RL, Berge JM, Berry V, Boyd HF, Brown MJ, Elder JS, Forrest AK, Fosberry AP, Gentry DR, Hibbs MJ, Jaworski DD, O\u2019Hanlon PJ, Pope AJ, Rittenhouse S, Sheppard RJ, Slater-Radosti C, Worby A (2002) Nanomolar Inhibitors of Staphylococcus aureus methionyl tRNA synthetase with Potent antibacterial activity against gram-positive pathogens. J Med Chem 45:1959\u20131962","journal-title":"J Med Chem"},{"key":"333_CR49","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1128\/AAC.02220-13","volume":"59","author":"T Hussain","year":"2015","unstructured":"Hussain T, Yogavel M, Sharma A (2015) Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases. Antimicrob Agents Chemother 59:1856\u20131867","journal-title":"Antimicrob Agents Chemother"},{"key":"333_CR50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baraga\u00f1a","year":"2015","unstructured":"Baraga\u00f1a B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522:315\u2013320","journal-title":"Nature"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-020-00333-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-020-00333-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-020-00333-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:18:04Z","timestamp":1629764284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-020-00333-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s10822-020-00333-x","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"9 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Robert Clark, Michael Lawless, and Walter Woltosz are employees of Simulations Plus, Inc. and own stock and\/or options in the company. The authors declare no other conflicts of interest or competing interests beyond those implicit in their employment by their respective institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}